PT1682907E - Método para identificar um indivíduo em risco de desenvolver insuficiência cardíaca pela determinação do nível de galectina-3 ou trombospondina-2 - Google Patents

Método para identificar um indivíduo em risco de desenvolver insuficiência cardíaca pela determinação do nível de galectina-3 ou trombospondina-2 Download PDF

Info

Publication number
PT1682907E
PT1682907E PT04765681T PT04765681T PT1682907E PT 1682907 E PT1682907 E PT 1682907E PT 04765681 T PT04765681 T PT 04765681T PT 04765681 T PT04765681 T PT 04765681T PT 1682907 E PT1682907 E PT 1682907E
Authority
PT
Portugal
Prior art keywords
level
risk
subject
determining
galectin
Prior art date
Application number
PT04765681T
Other languages
English (en)
Portuguese (pt)
Inventor
Yigal M Pinto
Original Assignee
Univ Maastricht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maastricht filed Critical Univ Maastricht
Publication of PT1682907E publication Critical patent/PT1682907E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
PT04765681T 2003-10-09 2004-09-27 Método para identificar um indivíduo em risco de desenvolver insuficiência cardíaca pela determinação do nível de galectina-3 ou trombospondina-2 PT1682907E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03078161A EP1522857A1 (en) 2003-10-09 2003-10-09 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2

Publications (1)

Publication Number Publication Date
PT1682907E true PT1682907E (pt) 2012-02-03

Family

ID=34306912

Family Applications (2)

Application Number Title Priority Date Filing Date
PT04765681T PT1682907E (pt) 2003-10-09 2004-09-27 Método para identificar um indivíduo em risco de desenvolver insuficiência cardíaca pela determinação do nível de galectina-3 ou trombospondina-2
PT101863314T PT2317324E (pt) 2003-10-09 2004-09-27 Método para identificar um indivíduo em risco de desenvolver insuficiência cardíaca pela determinação do nível de galectina-3 ou trombospondina-2

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT101863314T PT2317324E (pt) 2003-10-09 2004-09-27 Método para identificar um indivíduo em risco de desenvolver insuficiência cardíaca pela determinação do nível de galectina-3 ou trombospondina-2

Country Status (14)

Country Link
US (5) US7888137B2 (enExample)
EP (4) EP1522857A1 (enExample)
JP (5) JP4840744B2 (enExample)
CN (2) CN1879022B (enExample)
AT (1) ATE532073T1 (enExample)
AU (2) AU2004284496C1 (enExample)
CA (2) CA2842308A1 (enExample)
CY (2) CY1112359T1 (enExample)
DK (2) DK1682907T3 (enExample)
ES (2) ES2530567T3 (enExample)
PL (2) PL1682907T3 (enExample)
PT (2) PT1682907E (enExample)
SI (2) SI2317324T1 (enExample)
WO (1) WO2005040817A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
AU2007301981A1 (en) * 2006-09-25 2008-04-03 Universiteit Maastricht Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
WO2008091948A2 (en) * 2007-01-23 2008-07-31 University Of Virginia Patent Foundation Galectin-3-binding, protein as a biomarker of cardiovascular disease
CA2698899A1 (en) * 2007-09-17 2009-03-26 Bg Medicine, Inc. Assessing congestive heart risk in patients treated or potentially to be treated with a peroxisome-proliferator-activator-receptor-gamma agonist or a thiazolidinedione
CA2742265C (en) * 2008-10-29 2014-07-15 Bg Medicine, Inc. Galectin-3 immunoassay
EP2470911B1 (en) 2009-08-25 2016-04-20 BG Medicine, Inc. Galectin-3 and cardiac resynchronization therapy
WO2012003475A1 (en) 2010-07-02 2012-01-05 Bg Medicine, Inc. Statin therapy monitored by galectin- 3 measurement
US8703433B2 (en) * 2010-10-18 2014-04-22 Hideaki Hara Marker for amyotrophic lateral sclerosis, and use thereof
EP2460890A1 (en) 2010-12-01 2012-06-06 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Gpnmb/Osteoactivin as a drug target and biomarker in cardiac diseases
EP2671080A1 (en) * 2011-01-31 2013-12-11 BG Medicine, Inc. Use of galectin-3 for detecting and prognosing heart failure after acute coronary syndrome
EP2686689B1 (en) 2011-03-17 2019-08-07 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
AR086543A1 (es) * 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
JP6276701B2 (ja) * 2011-12-08 2018-02-07 エリアス・セラピューティクス・インコーポレイテッドＥｌｉａｚ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 血漿交換療法によるガレクチン−３レベルの低減
EP2900267B1 (en) * 2012-09-27 2019-05-15 Siemens Healthcare Diagnostics Inc. Cystatin c and galectin-3 as biomarkers for pulmonary arterial hypertension
CA2926480A1 (en) * 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
AU2016207734A1 (en) 2015-01-18 2017-08-03 Diasorin S.P.A. Use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker
US10688565B2 (en) * 2015-05-28 2020-06-23 Kyocera Corporation Cutting tool
CN112553335A (zh) * 2020-12-17 2021-03-26 核工业总医院 肾细胞癌生物标志物及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632901A (en) * 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU2684488A (en) * 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US6319676B1 (en) * 1995-05-02 2001-11-20 Carter Wallace, Inc. Diagnostic detection device and method
BE1010935A7 (nl) * 1997-02-19 1999-03-02 Delanghe Joris Richard Siegfri Fenotypering van humaan haptoglobine in serum of plasma door middel van quantitatieve agglutinatie met streptococcus antigenen.
US6210976B1 (en) * 1997-06-10 2001-04-03 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
US20060166276A1 (en) * 1997-09-05 2006-07-27 Lung Health Diagnostics Pty Ltd Method of diagnosis and agents useful for same
IL134880A0 (en) * 1997-09-05 2001-05-20 Univ Southern Australia A method of diagnosis
AU751660B2 (en) * 1997-10-24 2002-08-22 Shionogi & Co., Ltd. Method for inhibiting decomposition of natriuretic peptides and improved method for assaying natriuretic peptides with the use of the same
WO1999051260A2 (en) * 1998-04-02 1999-10-14 Genentech, Inc. Treatment of cardiac hypertrophy
CA2359667C (en) * 1999-01-29 2009-10-20 Roche Diagnostics Gmbh Method of identifying n-terminal probnp
AU3704500A (en) * 1999-02-19 2001-01-22 University Of Iowa Research Foundation, The Diagnostics and therapeutics for arterial wall disruptive disorders
JP2003507076A (ja) * 1999-08-20 2003-02-25 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 心臓の遺伝子発現の調節におけるｈｄａｃ４およびｈｄａｃ５
US20020081590A1 (en) 2000-02-04 2002-06-27 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
EP1358347A2 (en) 2000-04-05 2003-11-05 Incyte Genomics, Inc. Genes expressed in foam cell differentiation
KR100395254B1 (ko) * 2000-10-30 2003-08-21 (주)자리타 바이오텍 종양 발생 예측 키트
US7432060B2 (en) * 2000-11-09 2008-10-07 The Brigham And Women's Hospital, Inc. Methods for diagnosis of cardiovascular disease
AU2002220266A1 (en) * 2000-11-09 2002-05-21 Millennium Pharmaceuticals, Inc. Methods for the identification and the treatment of cardiovascular disease
DE60144493D1 (de) * 2000-12-08 2011-06-01 Curagen Corp Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
JP4035562B2 (ja) * 2001-01-31 2008-01-23 国立大学法人富山大学 ガレクチン−３誘導能を利用した物質のスクリーニング方法、肝の状態の診断方法およびこれらの方法を利用したキット
WO2002074911A2 (en) 2001-03-19 2002-09-26 Wisconsin Alumni Research Foundation Identification of gene expression alterations underlying the aging process in mammals
US20060019235A1 (en) 2001-07-02 2006-01-26 The Board Of Trustees Of The Leland Stanford Junior University Molecular and functional profiling using a cellular microarray
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
US20030099958A1 (en) * 2001-09-05 2003-05-29 Vitivity, Inc. Diagnosis and treatment of vascular disease
GB0124145D0 (en) 2001-10-08 2001-11-28 Bayer Ag Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
US20060141493A1 (en) 2001-11-09 2006-06-29 Duke University Office Of Science And Technology Atherosclerotic phenotype determinative genes and methods for using the same
US7294652B2 (en) * 2002-05-13 2007-11-13 Arexis Ab Autoimmune conditions and NADPH oxidase defects
AU2003290537A1 (en) 2002-10-24 2004-05-13 Duke University Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications
BR0316111A (pt) 2002-11-21 2005-09-13 Wyeth Corp Métodos para diagnosticar rcc e outros tumores sólidos
EP1431399A1 (en) * 2002-12-20 2004-06-23 Clinigenetics Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
US6889083B2 (en) * 2003-04-21 2005-05-03 Medtronic, Inc. Atrial tracking recovery to restore cardiac resynchronization therapy in dual chamber tracking modes
WO2005020784A2 (en) 2003-05-23 2005-03-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
WO2004111654A2 (en) 2003-06-06 2004-12-23 Ciphergen Biosystems, Inc. Serum biomarkers in ischaemic heart disease
US20050106100A1 (en) 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
EP1560025A3 (en) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Specific markers for diabetes
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
DE10347436B4 (de) * 2003-10-13 2007-08-02 Johann Wolfgang Goethe-Universität Frankfurt am Main In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
EP1720562A4 (en) 2004-01-15 2009-10-28 Scios Inc METHOD FOR TREATING CARDIAL REMODELING AFTER MYOCARDIAL DAMAGE
WO2006026074A2 (en) 2004-08-04 2006-03-09 Duke University Atherosclerotic phenotype determinative genes and methods for using the same
AU2006210794A1 (en) 2005-02-01 2006-08-10 Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Biomarkers for tissue status
US20070092886A1 (en) 2005-03-22 2007-04-26 Raymond Tabibiazar Methods and compositions for diagnosis, monitoring and development of therapeutics for treatment of atherosclerotic disease
US7632634B2 (en) 2005-04-15 2009-12-15 University Of Maryland Biotechnology Institute Method and assay for early diagnosis of prostate cancer
US9592970B2 (en) * 2008-07-17 2017-03-14 Toby D. Henderson Robotic gantry with end effector for product lifting
CA2742265C (en) * 2008-10-29 2014-07-15 Bg Medicine, Inc. Galectin-3 immunoassay
EP2470911B1 (en) * 2009-08-25 2016-04-20 BG Medicine, Inc. Galectin-3 and cardiac resynchronization therapy

Also Published As

Publication number Publication date
AU2004284496B2 (en) 2009-08-06
CA2842308A1 (en) 2005-05-06
ES2377012T3 (es) 2012-03-21
HK1101426A1 (en) 2007-10-18
CN102998458A (zh) 2013-03-27
SI1682907T1 (sl) 2012-03-30
EP1522857A1 (en) 2005-04-13
JP5789009B2 (ja) 2015-10-07
AU2009227844B2 (en) 2012-07-19
PT2317324E (pt) 2015-02-17
CN1879022B (zh) 2012-10-17
JP5580774B2 (ja) 2014-08-27
SI2317324T1 (sl) 2015-11-30
EP2317324B1 (en) 2014-11-12
US20130189716A1 (en) 2013-07-25
CY1112359T1 (el) 2015-12-09
ES2530567T3 (es) 2015-03-03
US20080193954A1 (en) 2008-08-14
EP2919012A1 (en) 2015-09-16
WO2005040817A1 (en) 2005-05-06
US20110104722A1 (en) 2011-05-05
PL2317324T3 (pl) 2015-10-30
CA2542033A1 (en) 2005-05-06
AU2004284496A1 (en) 2005-05-06
CA2542033C (en) 2014-04-29
US20120220532A1 (en) 2012-08-30
JP2011177184A (ja) 2011-09-15
AU2009227844A1 (en) 2009-11-26
EP2317324A1 (en) 2011-05-04
CY1116147T1 (el) 2017-02-08
DK2317324T3 (en) 2015-02-16
CN102998458B (zh) 2015-07-22
ATE532073T1 (de) 2011-11-15
JP2015171365A (ja) 2015-10-01
EP1682907A1 (en) 2006-07-26
US20150037353A1 (en) 2015-02-05
AU2004284496C1 (en) 2010-03-04
JP2014115297A (ja) 2014-06-26
JP2007508527A (ja) 2007-04-05
US7888137B2 (en) 2011-02-15
HK1184534A1 (zh) 2014-01-24
DK1682907T3 (da) 2012-08-13
CN1879022A (zh) 2006-12-13
PL1682907T3 (pl) 2012-03-30
EP1682907B1 (en) 2011-11-02
US8084276B2 (en) 2011-12-27
JP2010279378A (ja) 2010-12-16
JP4840744B2 (ja) 2011-12-21

Similar Documents

Publication Publication Date Title
SI2317324T1 (sl) Postopek identifikacije subjekta, ki mu grozi nevarnost srčne odpovedi z ugotavljanjem nivoja galektina-3 ali trombospondina-2
DK1734368T3 (da) Annexin-autoantistoffer anvendt som markörer for lungecancer
AU2002902A (en) Method for differentiating irritable bowel syndrome from inflammatory bowel disease (ibd) and for monitoring persons with ibd using total endogenous lactoferrinas a marker
EP2306192A3 (en) Risk Markers For Cardiovascular Disease
ATE111228T1 (de) Verfahren zur überwachung des kollagenabbaus.
WO2008120684A1 (ja) 急性中枢神経障害の予後判定方法
WO1999057306A3 (en) Method for diagnosing a vascular condition
AU2003265768A1 (en) Automated framework for the analysis of biological data
CA2271544A1 (en) Method to detect bone and other connective tissue disorders in humans and animals
EP1132483A3 (en) Method for diagnosing schizophrenia using objective indices
CY1105025T1 (el) Αναλυση λεπτινης βασιζομενη στην ανιχνευση εκφρασης ang-2
EP1612559A4 (en) METHOD FOR EVALUATING THE ANTIOXIDATION POTENTIAL OF A BIOLOGICAL SAMPLE
DE50303798D1 (de) Vorrichtung, um in einem Zielgebiet eines menschlichen oder tierischen Körpers einen künstlichen isolierten Kreislauf zu etablieren
CA2243372A1 (en) Methods of diagnosing muscle damage
ATE421693T1 (de) Proteine in der diabetes-proteomanalyse
WO2006117688A3 (en) Diagnosis of heart failure
WO2003068958A1 (fr) Procede d'analyse d'un acide nucleique specifiant un gene presentant une modification de son niveau d'expression liee a la schizophrenie
EP1445327A4 (en) SCREENING METHOD FOR A MEDICAMENT ACTIVE ON THE CELL WALL
WO2005005957A3 (en) Method of detecting cancer using delta-catenin
CA2297361A1 (en) Methods of diagnosing muscle damage
WO2005043168A3 (en) Method for distinguishing aml-specific flt3 length mutations from tkd mutations
DE60326269D1 (de) Verfahren zur detektion von prpsc unter verwendung von gruppe ii aminoglykosid antibiotika
WO2005060627A3 (en) Methods of assessing the risk of non-traumatic bone fracture
WO2005000099A3 (en) BLOOD FACTOR DOMAINS (BFDs)
WO2004070345A3 (en) Age determination on death